D&A at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AmortizationOfIntangibleAssets.
The official record: Xeris Biopharma Holdings, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xeris Biopharma Holdings, Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xeris Biopharma Holdings, Inc.'s D&A?
- Xeris Biopharma Holdings, Inc. (XERS) reported D&A of $2.71M in Q1 2026.
- How has Xeris Biopharma Holdings, Inc.'s D&A changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s D&A decreased by 0.0% year-over-year, from $2.71M to $2.71M.
- What is the long-term trend for Xeris Biopharma Holdings, Inc.'s D&A?
- Over 4 years (2021 to 2025), Xeris Biopharma Holdings, Inc.'s D&A has grown at a 110.7% compound annual growth rate (CAGR), from $550K to $10.84M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.